Chemo-enzymatic cascade processes are invaluable due to their ability to rapidly construct high-value products from available feedstock chemicals in a one-pot relay manner. In a patent, 22013-33-8, name is 2,3-Dihydrobenzo[b][1,4]dioxin-6-amine, introducing its new discovery. Quality Control of 2,3-Dihydrobenzo[b][1,4]dioxin-6-amine
4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidine has been linked to various arylcarbamates to obtain compounds having affinity for dopamine-D1 and -D2, serotonin 5HT(2A) and alpha1-adrenoceptors. When linkers with restricted flexibility are used, the biological activity is reduced indicating that a bended conformation is needed in this series of bioactive molecules. Compounds with a relatively low D2/5HT(2A) affinity ratio in receptor binding experiments and high affinity for the alpha1-adrenoceptors exhibit a pharmacological profile which suggests a preferential effect on the mesocorticolimbic dopaminergic system and an ‘atypical’ antipsychotic activity.
You can get involved in discussing the latest developments in this exciting area about 22013-33-8 Quality Control of 2,3-Dihydrobenzo[b][1,4]dioxin-6-amine